Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | NOS1 | P29475 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9996050 | 0.98 | TBXAS1 (0.97) | TBXAS1LTA4HKMT2AKDM4EALDH1A1 | |
| SCHEMBL12045305 | 0.92 | TBXAS1 (0.84) | TBXAS1LTA4HKMT2AKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL9996074 | 0.90 | TBXAS1 (0.82) | TBXAS1LTA4HKMT2AKDM4EMEN1 | |
| SCHEMBL12045307 | 0.90 | TBXAS1 (0.82) | TBXAS1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL10476929 | 0.89 | TBXAS1 (0.79) | TBXAS1KMT2AKDM4EALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL9996079 | 0.89 | TBXAS1 (0.79) | TBXAS1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL7132156 | 0.88 | LTA4H (1.00) | TBXAS1LTA4HKMT2AKDM4EALDH1A1 | |
| SCHEMBL8638819 | 0.86 | CACNA1B (0.77) | TBXAS1LTA4HKMT2AKDM4EMEN1 | |
| SCHEMBL8685423 | 0.84 | TBXAS1 (0.80) | TBXAS1LTA4HKMT2AMEN1LMNA | |
| SCHEMBL9260489 | 0.84 | TBXAS1 (0.71) | TBXAS1KDM4EALDH1A1LMNANOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108623616-B | Imidazole cyclophane receptor, synthetic method thereof and application of imidazole cyclophane receptor in recognition of iron ions and dihydrogen phosphate ions | 福州大学 | 2021-04-27 | — | — | CN | claimed |
| CN-108623616-B | Imidazole cyclophane receptor, synthetic method thereof and application of imidazole cyclophane receptor in recognition of iron ions and dihydrogen phosphate ions | 福州大学 | 2021-04-27 | — | — | CN | disclosed |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-9388179-B2 | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150284389-A1 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| EP-0175363-B1 | 4,5-DIHYDRO-3(2H)-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4816454-A | CARDIOVASCULAR DISORDERS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1989-03-28 | — | — | US | disclosed |
| US-4636500-A | N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromboxane synthetase enzyme and pharmaceutical compositions thereof | PFIZER INC. (US) | 1987-01-13 | — | — | US | disclosed |
| US-4602016-A | N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromboxane synthetase enzyme and pharmaceutical compositions thereof | PFIZER INC. (US) | 1986-07-22 | — | — | US | disclosed |
| US-4528195-A | Imidazole derivatives and salts thereof, their synthesis and intermediates and pharmaceutical formulations | THOROGOOD PETER B (GB) | 1985-07-09 | — | — | US | disclosed |
| EP-0003560-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| US-4416895-A | ANTICOAGULANTS, ANTISHOCK AGENTS | BURROUGHS WELLCOME CO. (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0003560-A2 | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | TBXAS1 469/4885LTA4H 1955/4885KMT2A 4262/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TBXAS1 1071/4885LTA4H 1968/4885KMT2A 3654/4885 |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TBXAS1 265/4885LTA4H 2984/4885KMT2A 710/4885 |
| US-20150284389-A1 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN1B, SCN1A, SCN2B | TBXAS1 1459/4885LTA4H 2075/4885KMT2A 1466/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TBXAS1 265/4885LTA4H 2984/4885KMT2A 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.